Compare CSX Corporation (CSX) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
CSX Corporation vs TG Therapeutics Inc — how do they compare? CSX Corporation trades at $50.1 (market cap $92.55B), while TG Therapeutics Inc trades at $49.44 (market cap $7.64B). The key difference: CSX Corporation is far larger — about 12.1× TG Therapeutics Inc's market cap, and CSX Corporation pays a 1.12% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| CSX | TGTX | |
|---|---|---|
Market Cap | $92.55B | $7.64B |
Sector | Industrials | Health |
52-Week High | $53.21 | $59.06 |
52-Week Low | $32.05 | $26.94 |
Enterprise Value | $110.52B | $7.84B |
Dividend Yield | 1.12% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CSX trades at $50.09, down slightly by 0.06% today, with a neutral technical signal. Recent Q2 2026 earnings beat expectations with EPS of $0.54 versus $0.518 expected, driven by 10% revenue growth and improved margins. Analyst consensus is bullish with a $52.57 price target, supported by strong cash flow trends and a 58.69% buy rating from coverage.
The outlook is positive due to volume growth and cost controls, but risks include fuel cost pressures and competitive freight markets. With a P/E of 29.05 above industry averages, the stock offers growth potential if earnings momentum continues, though high debt levels warrant monitoring.
TG Therapeutics (TGTX) trades at $49.50, up 0.69% today, with a bearish technical signal from moving averages despite neutral oscillators. The company reported strong revenue growth, with Q2 2026 sales reaching $240 million and raised full-year guidance to $950 million, though it missed earnings estimates for three consecutive quarters. Profitability metrics remain robust with a net income margin of 55.22% and ROE exceeding 100%, but valuation ratios like EV/EBITDA at 56.26 suggest premium pricing.
The outlook is mixed: bullish analyst sentiment with an 84.6% buy rating and a $63.75 price target offers upside potential, driven by Briumvi's commercial success and expansion into schizophrenia trials. However, risks include earnings misses, a shareholder investigation into fiduciary duties, and high cash burn in 2025. Investors should weigh strong revenue momentum against execution risks and elevated valuations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About CSX Corporation
Operating in the Eastern United States, Class I railroad CSX generated revenue near $12.5 billion in 2021. On its more than 21,000 miles of track, CSX hauls shipments of coal (13% of consolidated revenue), chemicals (22%), intermodal containers (16%), automotive cargo (9%), and a diverse mix of other bulk and industrial merchandise.
Read more on CSX →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
